The ISOC1 Knockout HT29 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal population of HT29 colorectal adenocarcinoma cells carrying disrupted ISOC1 alleles. This heterogeneous knockout pool eliminates the need for single-cell cloning and provides a robust loss-of-function model for studying ISOC1-dependent processes. The polyclonal format recapitulates the average phenotypic outcome of ISOC1 ablation across a mixture of edited genotypes in the HT29 epithelial tumorigenic background.
The HT29 host cell line is derived from human colorectal adenocarcinoma and displays a differentiated epithelial morphology upon confluence. Known for its mutations in BRAF (V600E), APC, and TP53, HT29 is a benchmark model in cancer research, particularly for investigating oncogenic signaling and tumor metabolism. Its well-characterized growth properties and ease of genome editing make it an ideal platform for generating knockout cell pools like this ISOC1-targeted population.
ISOC1 encodes a mitochondrial isochorismatase-domain protein implicated in nucleotide synthesis and small-molecule metabolism. As a transcriptional target of the MYC oncoprotein, ISOC1 is part of the MYC-driven metabolic program that supports rapid proliferation. In colorectal cancer cells such as HT29, MYC is frequently overactive, and ISOC1 may act as a downstream mediator bridging MYC signaling to essential anabolic outputs, including nucleotide pool maintenance.
Ablation of ISOC1 in the HT29 background disrupts the MYC?CISOC1 metabolic axis, potentially impairing nucleotide biosynthesis and cell growth. Given HT29??s coexisting mutations in BRAF, APC, and TP53, this knockout model offers a clinically relevant context to examine whether ISOC1 contributes to metabolic vulnerabilities in genetically complex colorectal tumors. The polyclonal population facilitates the study of ISOC1??s role without clonal artifacts, highlighting its significance in cancer metabolism.
This ISOC1 knockout product is suitable for a range of functional assays, including cell proliferation analysis, apoptosis detection, Western blotting of MYC targets, and metabolic profiling of nucleotide pools. It serves applications in cancer metabolism research, MYC signaling dissection, and colorectal tumor functional genomics, including combinatorial drug studies. Researchers may also use it for high-throughput small-molecule screens to identify synthetically lethal interactions. For more information or technical assistance, please contact Ascent Research.
